Research Insights

NIH: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)

The purpose of this program is to accelerate the development of Digital Therapeutics to treat Substance Use Disorders.

Amount: $1,510,000 (UG3 Phase); Unspecified (UH3 Phase)

Due Date: 06/17/2024 (LOI); 07/17/2024 (Full Proposal)